A landmark series of Phase 3 randomized controlled trials has revealed that finerenone, a selective mineralocorticoid receptor antagonist, delivers significant clinical benefits for patients with non-diabetic chronic kidney disease—a population historically constrained by limited therapeutic options. The studies, involving over 9,400 patients across 37 countries, demonstrated a 23% reduction in kidney disease progression when compared to placebo, according to findings published in The New England Journal of Medicine.
Beyond renal protection, finerenone reduced cardiovascular death risk by 14% across both diabetic and non-diabetic populations, addressing a critical comorbidity burden in kidney disease patients. These results suggest the drug’s mechanism of action addresses fundamental pathophysiological processes independent of diabetes status. With a manageable safety profile, finerenone represents a meaningful advance for CKD patients who have exhausted conventional treatments such as ACE inhibitors and angiotensin receptor blockers.
Read the full article on GMJ Newsroom.
Was this article helpful?
